A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
Identifieur interne : 000926 ( Ncbi/Merge ); précédent : 000925; suivant : 000927A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
Auteurs : Karen M. Megazzini [États-Unis] ; Moses Sinkala ; Sten H. Vermund ; David T. Redden ; Daniel W. Krebs ; Edward P. Acosta ; Joyce Mwanza ; Robert L. Goldenberg ; Namwinga Chintu ; Marc Bulterys ; Jeffrey Sa StringerSource :
- AIDS (London, England) [ 1473-5571 ] ; 2010.
Descripteurs français
- KwdFr :
- Accessibilité des services de santé, Adulte, Agents antiVIH (usage thérapeutique), Complications de la grossesse et maladies infectieuses (traitement médicamenteux), Complications de la grossesse et maladies infectieuses (virologie), Complications de la grossesse et maladies infectieuses (épidémiologie), Femelle, Grossesse, Humains, Infections à VIH (), Infections à VIH (transmission), Infections à VIH (épidémiologie), Névirapine (usage thérapeutique), Prise en charge prénatale (), Prophylaxie après exposition, Résultat thérapeutique, Sang foetal (virologie), Transmission verticale de maladie infectieuse (), Zambie (épidémiologie).
- MESH :
- traitement médicamenteux : Complications de la grossesse et maladies infectieuses.
- usage thérapeutique : Agents antiVIH, Infections à VIH, Névirapine.
- virologie : Complications de la grossesse et maladies infectieuses, Sang foetal.
- épidémiologie : Complications de la grossesse et maladies infectieuses, Infections à VIH, Zambie.
- Accessibilité des services de santé, Adulte, Femelle, Grossesse, Humains, Infections à VIH, Prise en charge prénatale, Prophylaxie après exposition, Résultat thérapeutique, Transmission verticale de maladie infectieuse.
- Wicri :
- geographic : Zambie.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (therapeutic use), Female, Fetal Blood (virology), HIV Infections (epidemiology), HIV Infections (prevention & control), HIV Infections (transmission), Health Services Accessibility, Humans, Infectious Disease Transmission, Vertical (prevention & control), Nevirapine (therapeutic use), Post-Exposure Prophylaxis, Pregnancy, Pregnancy Complications, Infectious (drug therapy), Pregnancy Complications, Infectious (epidemiology), Pregnancy Complications, Infectious (virology), Prenatal Care (methods), Treatment Outcome, Zambia (epidemiology).
- MESH :
- chemical , therapeutic use : Anti-HIV Agents, Nevirapine.
- geographic , epidemiology : Zambia.
- drug therapy : Pregnancy Complications, Infectious.
- epidemiology : HIV Infections, Pregnancy Complications, Infectious.
- methods : Prenatal Care.
- prevention & control : HIV Infections, Infectious Disease Transmission, Vertical.
- transmission : HIV Infections.
- virology : Fetal Blood, Pregnancy Complications, Infectious.
- Adult, Female, Health Services Accessibility, Humans, Post-Exposure Prophylaxis, Pregnancy, Treatment Outcome.
Abstract
Determine whether enhanced labor ward-based services for prevention of mother-to-child transmission of HIV (PMTCT) would improve nevirapine (NVP) coverage.
DOI: 10.1097/QAD.0b013e328334b285
PubMed: 19926959
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000127
- to stream PubMed, to step Curation: 000127
- to stream PubMed, to step Checkpoint: 000127
Links to Exploration step
pubmed:19926959Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.</title><author><name sortKey="Megazzini, Karen M" sort="Megazzini, Karen M" uniqKey="Megazzini K" first="Karen M" last="Megazzini">Karen M. Megazzini</name><affiliation wicri:level="2"><nlm:affiliation>University of Alabama at Birmingham, Schools of Public Health and Medicine, Birmingham, Alabama, USA. KMegazzini@gmail.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Alabama at Birmingham, Schools of Public Health and Medicine, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Sinkala, Moses" sort="Sinkala, Moses" uniqKey="Sinkala M" first="Moses" last="Sinkala">Moses Sinkala</name></author><author><name sortKey="Vermund, Sten H" sort="Vermund, Sten H" uniqKey="Vermund S" first="Sten H" last="Vermund">Sten H. Vermund</name></author><author><name sortKey="Redden, David T" sort="Redden, David T" uniqKey="Redden D" first="David T" last="Redden">David T. Redden</name></author><author><name sortKey="Krebs, Daniel W" sort="Krebs, Daniel W" uniqKey="Krebs D" first="Daniel W" last="Krebs">Daniel W. Krebs</name></author><author><name sortKey="Acosta, Edward P" sort="Acosta, Edward P" uniqKey="Acosta E" first="Edward P" last="Acosta">Edward P. Acosta</name></author><author><name sortKey="Mwanza, Joyce" sort="Mwanza, Joyce" uniqKey="Mwanza J" first="Joyce" last="Mwanza">Joyce Mwanza</name></author><author><name sortKey="Goldenberg, Robert L" sort="Goldenberg, Robert L" uniqKey="Goldenberg R" first="Robert L" last="Goldenberg">Robert L. Goldenberg</name></author><author><name sortKey="Chintu, Namwinga" sort="Chintu, Namwinga" uniqKey="Chintu N" first="Namwinga" last="Chintu">Namwinga Chintu</name></author><author><name sortKey="Bulterys, Marc" sort="Bulterys, Marc" uniqKey="Bulterys M" first="Marc" last="Bulterys">Marc Bulterys</name></author><author><name sortKey="Stringer, Jeffrey Sa" sort="Stringer, Jeffrey Sa" uniqKey="Stringer J" first="Jeffrey Sa" last="Stringer">Jeffrey Sa Stringer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:19926959</idno><idno type="pmid">19926959</idno><idno type="doi">10.1097/QAD.0b013e328334b285</idno><idno type="wicri:Area/PubMed/Corpus">000127</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000127</idno><idno type="wicri:Area/PubMed/Curation">000127</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000127</idno><idno type="wicri:Area/PubMed/Checkpoint">000127</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000127</idno><idno type="wicri:Area/Ncbi/Merge">000926</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.</title><author><name sortKey="Megazzini, Karen M" sort="Megazzini, Karen M" uniqKey="Megazzini K" first="Karen M" last="Megazzini">Karen M. Megazzini</name><affiliation wicri:level="2"><nlm:affiliation>University of Alabama at Birmingham, Schools of Public Health and Medicine, Birmingham, Alabama, USA. KMegazzini@gmail.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Alabama at Birmingham, Schools of Public Health and Medicine, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Sinkala, Moses" sort="Sinkala, Moses" uniqKey="Sinkala M" first="Moses" last="Sinkala">Moses Sinkala</name></author><author><name sortKey="Vermund, Sten H" sort="Vermund, Sten H" uniqKey="Vermund S" first="Sten H" last="Vermund">Sten H. Vermund</name></author><author><name sortKey="Redden, David T" sort="Redden, David T" uniqKey="Redden D" first="David T" last="Redden">David T. Redden</name></author><author><name sortKey="Krebs, Daniel W" sort="Krebs, Daniel W" uniqKey="Krebs D" first="Daniel W" last="Krebs">Daniel W. Krebs</name></author><author><name sortKey="Acosta, Edward P" sort="Acosta, Edward P" uniqKey="Acosta E" first="Edward P" last="Acosta">Edward P. Acosta</name></author><author><name sortKey="Mwanza, Joyce" sort="Mwanza, Joyce" uniqKey="Mwanza J" first="Joyce" last="Mwanza">Joyce Mwanza</name></author><author><name sortKey="Goldenberg, Robert L" sort="Goldenberg, Robert L" uniqKey="Goldenberg R" first="Robert L" last="Goldenberg">Robert L. Goldenberg</name></author><author><name sortKey="Chintu, Namwinga" sort="Chintu, Namwinga" uniqKey="Chintu N" first="Namwinga" last="Chintu">Namwinga Chintu</name></author><author><name sortKey="Bulterys, Marc" sort="Bulterys, Marc" uniqKey="Bulterys M" first="Marc" last="Bulterys">Marc Bulterys</name></author><author><name sortKey="Stringer, Jeffrey Sa" sort="Stringer, Jeffrey Sa" uniqKey="Stringer J" first="Jeffrey Sa" last="Stringer">Jeffrey Sa Stringer</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (therapeutic use)</term><term>Female</term><term>Fetal Blood (virology)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (prevention & control)</term><term>HIV Infections (transmission)</term><term>Health Services Accessibility</term><term>Humans</term><term>Infectious Disease Transmission, Vertical (prevention & control)</term><term>Nevirapine (therapeutic use)</term><term>Post-Exposure Prophylaxis</term><term>Pregnancy</term><term>Pregnancy Complications, Infectious (drug therapy)</term><term>Pregnancy Complications, Infectious (epidemiology)</term><term>Pregnancy Complications, Infectious (virology)</term><term>Prenatal Care (methods)</term><term>Treatment Outcome</term><term>Zambia (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Adulte</term><term>Agents antiVIH (usage thérapeutique)</term><term>Complications de la grossesse et maladies infectieuses (traitement médicamenteux)</term><term>Complications de la grossesse et maladies infectieuses (virologie)</term><term>Complications de la grossesse et maladies infectieuses (épidémiologie)</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (transmission)</term><term>Infections à VIH (épidémiologie)</term><term>Névirapine (usage thérapeutique)</term><term>Prise en charge prénatale ()</term><term>Prophylaxie après exposition</term><term>Résultat thérapeutique</term><term>Sang foetal (virologie)</term><term>Transmission verticale de maladie infectieuse ()</term><term>Zambie (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Nevirapine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Zambia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Prenatal Care</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term><term>Infectious Disease Transmission, Vertical</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Complications de la grossesse et maladies infectieuses</term></keywords><keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Infections à VIH</term><term>Névirapine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Complications de la grossesse et maladies infectieuses</term><term>Sang foetal</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Fetal Blood</term><term>Pregnancy Complications, Infectious</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Complications de la grossesse et maladies infectieuses</term><term>Infections à VIH</term><term>Zambie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Health Services Accessibility</term><term>Humans</term><term>Post-Exposure Prophylaxis</term><term>Pregnancy</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Adulte</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Infections à VIH</term><term>Prise en charge prénatale</term><term>Prophylaxie après exposition</term><term>Résultat thérapeutique</term><term>Transmission verticale de maladie infectieuse</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Zambie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Determine whether enhanced labor ward-based services for prevention of mother-to-child transmission of HIV (PMTCT) would improve nevirapine (NVP) coverage.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19926959</PMID><DateCreated><Year>2010</Year><Month>01</Month><Day>20</Day></DateCreated><DateCompleted><Year>2011</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.</ArticleTitle><Pagination><MedlinePgn>447-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e328334b285</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Determine whether enhanced labor ward-based services for prevention of mother-to-child transmission of HIV (PMTCT) would improve nevirapine (NVP) coverage.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cluster-randomized trial at 12 public-sector delivery centers in Lusaka, Zambia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following a baseline surveillance period, 12 labor wards were randomized, six to offer opt-in HIV testing to women of unknown serostatus (with NVP administration as indicated) and to assess NVP adherence among known HIV-infected women. The six control labor wards provided the standard of care. The NVP coverage endpoint was defined as the proportion of HIV-infected/exposed women/infant pairs with confirmed NVP ingestion. We used generalized estimating equations (GEE) to determine the odds of coverage associated with the intervention and ultimately used the parameters for the estimated GEE model to estimate relative risk.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between October 2005 and January 2006, 7664 women gave birth at participating clinics. We collected anonymous-linked blood from 7592 (99%) umbilical cords; tested 7438 (97%) for HIV, 1618 (22%) were seropositive, and of these, 1279 (79%) were tested for NVP. At baseline (preintervention), the probability of HIV-infected/exposed women/infant pairs receiving NVP in treatment clinics (42%) was 0.89 times the probability of being covered in control clinics (53%) whereas during the intervention period the probability of treatment clinic coverage (52%) was 1.22 the probability control clinic coverage (43%), representing a multiplicative effect of 1.37 upon the RR at baseline (ratio of relative risks 1.37, bootstrapped 95% CI, 1.04-1.77).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Labor ward-based PMTCT programs are feasible and can have a significant, positive impact on NVP coverage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Megazzini</LastName><ForeName>Karen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham, Schools of Public Health and Medicine, Birmingham, Alabama, USA. KMegazzini@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinkala</LastName><ForeName>Moses</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vermund</LastName><ForeName>Sten H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Redden</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Krebs</LastName><ForeName>Daniel W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Acosta</LastName><ForeName>Edward P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Mwanza</LastName><ForeName>Joyce</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Chintu</LastName><ForeName>Namwinga</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bulterys</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Stringer</LastName><ForeName>Jeffrey Sa</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>99DK7FVK1H</RegistryNumber><NameOfSubstance UI="D019829">Nevirapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018445" MajorTopicYN="N">Infectious Disease Transmission, Vertical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019829" MajorTopicYN="N">Nevirapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056990" MajorTopicYN="N">Post-Exposure Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="N">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011295" MajorTopicYN="N">Prenatal Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015024" MajorTopicYN="N" Type="Geographic">Zambia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19926959</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e328334b285</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Alabama</li></region></list><tree><noCountry><name sortKey="Acosta, Edward P" sort="Acosta, Edward P" uniqKey="Acosta E" first="Edward P" last="Acosta">Edward P. Acosta</name><name sortKey="Bulterys, Marc" sort="Bulterys, Marc" uniqKey="Bulterys M" first="Marc" last="Bulterys">Marc Bulterys</name><name sortKey="Chintu, Namwinga" sort="Chintu, Namwinga" uniqKey="Chintu N" first="Namwinga" last="Chintu">Namwinga Chintu</name><name sortKey="Goldenberg, Robert L" sort="Goldenberg, Robert L" uniqKey="Goldenberg R" first="Robert L" last="Goldenberg">Robert L. Goldenberg</name><name sortKey="Krebs, Daniel W" sort="Krebs, Daniel W" uniqKey="Krebs D" first="Daniel W" last="Krebs">Daniel W. Krebs</name><name sortKey="Mwanza, Joyce" sort="Mwanza, Joyce" uniqKey="Mwanza J" first="Joyce" last="Mwanza">Joyce Mwanza</name><name sortKey="Redden, David T" sort="Redden, David T" uniqKey="Redden D" first="David T" last="Redden">David T. Redden</name><name sortKey="Sinkala, Moses" sort="Sinkala, Moses" uniqKey="Sinkala M" first="Moses" last="Sinkala">Moses Sinkala</name><name sortKey="Stringer, Jeffrey Sa" sort="Stringer, Jeffrey Sa" uniqKey="Stringer J" first="Jeffrey Sa" last="Stringer">Jeffrey Sa Stringer</name><name sortKey="Vermund, Sten H" sort="Vermund, Sten H" uniqKey="Vermund S" first="Sten H" last="Vermund">Sten H. Vermund</name></noCountry><country name="États-Unis"><region name="Alabama"><name sortKey="Megazzini, Karen M" sort="Megazzini, Karen M" uniqKey="Megazzini K" first="Karen M" last="Megazzini">Karen M. Megazzini</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000926 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000926 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19926959
|texte= A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19926959" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |